Literature DB >> 28578723

Pertussis diagnosis in Belgium: results of the National Reference Centre for Bordetella anno 2015.

H Martini1, C Rodeghiero2, C VAN DEN Poel2, M Vincent2, D Pierard1, K Huygen2.   

Abstract

In 2015, the Belgian National Reference Centre for Bordetella analyzed 4110 respiratory samples by qPCR and 4877 serum samples by serology. Whereas about 50% of respiratory samples were from infants and children below the age of five, serum samples were distributed among all age categories. A total of 394 (9·6%) cases was diagnosed as positive for Bordetella pertussis by qPCR and 844 (17·3%) cases were diagnosed as acute infection by serology (anti-pertussis toxin (PT) IgG > 125 IU/ml). Another 1042 (21·4%) sera had anti-PT IgG between 55 and 125 IU/ml reflecting a vaccination or pertussis infection during the last 1-2 years. Seventy per cent of the pertussis cases diagnosed by qPRC were in infants and children younger than 14 years old, whereas the highest number of sera with anti-PT levels >125 IU/ml was in the age group of 10-14 years old. Based on the limited data of the last vaccination (reported for only 15% of the samples), recent booster vaccination in the teenager group may have contributed only minimally to these elevated anti-PT levels. The highest number of sera with anti-PT titers between 55 and 125 IU/ml was found in the age category 50-59 years old. It is clear that pertussis continues to be a problem in Belgium and that other vaccination strategies (maternal vaccination, cocoon vaccination) and ultimately better vaccines will be needed to control this highly infectious respiratory disease.

Entities:  

Keywords:  zzm321990 Bordetella pertussiszzm321990

Mesh:

Year:  2017        PMID: 28578723      PMCID: PMC9148849          DOI: 10.1017/S0950268817001108

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  26 in total

1.  Maternal pertussis and influenza immunization coverage and attitude of health care workers towards these recommendations in Flanders, Belgium.

Authors:  Kirsten Maertens; Tessa Braeckman; Geert Top; Pierre Van Damme; Elke Leuridan
Journal:  Vaccine       Date:  2016-10-11       Impact factor: 3.641

2.  Pertussis serodiagnosis in Belgium from 1990 to 2009.

Authors:  Muriel Vincent; Caroline Rodeghiero; Romain Eylenbosch; Yvan Mans; Jeannine Swalus-Steenhouwer; Denis Piérard; Kris Huygen; Raymond Vanhoof
Journal:  Clin Vaccine Immunol       Date:  2011-02-23

Review 3.  Seroprevalence studies of pertussis: what have we learned from different immunized populations.

Authors:  Alex-Mikael Barkoff; Kirsi Gröndahl-Yli-Hannuksela; Qiushui He
Journal:  Pathog Dis       Date:  2015-07-24       Impact factor: 3.166

4.  Highlights of the 11th International Bordetella Symposium: from Basic Biology to Vaccine Development.

Authors:  Nicholas H Carbonetti; Carl Heinz Wirsing von König; Ruiting Lan; Francoise Jacob-Dubuisson; Peggy A Cotter; Rajendar Deora; Tod J Merkel; Cécile A van Els; Camille Locht; Daniela Hozbor; Maria E Rodriguez
Journal:  Clin Vaccine Immunol       Date:  2016-11-04

5.  High heterogeneity in methods used for the laboratory confirmation of pertussis diagnosis among European countries, 2010: integration of epidemiological and laboratory surveillance must include standardisation of methodologies and quality assurance.

Authors:  Q He; A M Barkoff; J Mertsola; S Glismann; S Bacci
Journal:  Euro Surveill       Date:  2012-08-09

6.  Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age.

Authors:  Kirsten Maertens; Raïssa Nadège Caboré; Kris Huygen; Sandra Vermeiren; Niel Hens; Pierre Van Damme; Elke Leuridan
Journal:  Vaccine       Date:  2016-04-30       Impact factor: 3.641

7.  Serodiagnosis of whooping cough in Belgium: results of the National Reference Centre for Bordetella pertussis anno 2013.

Authors:  Sophie Duterme; Raymond Vanhoof; Jean Vanderpas; Denis Pierard; Kris Huygen
Journal:  Acta Clin Belg       Date:  2016-02-06       Impact factor: 1.264

8.  A real-time PCR assay with improved specificity for detection and discrimination of all clinically relevant Bordetella species by the presence and distribution of three Insertion Sequence elements.

Authors:  Lieuwe Roorda; Johannes Buitenwerf; Jacobus M Ossewaarde; Anneke van der Zee
Journal:  BMC Res Notes       Date:  2011-01-21

9.  Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis.

Authors:  Sabine C de Greeff; Hester E de Melker; Pieter G M van Gageldonk; Joop F P Schellekens; Fiona R M van der Klis; Liesbeth Mollema; Frits R Mooi; Guy A M Berbers
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

10.  Global population structure and evolution of Bordetella pertussis and their relationship with vaccination.

Authors:  Marieke J Bart; Simon R Harris; Abdolreza Advani; Yoshichika Arakawa; Daniela Bottero; Valérie Bouchez; Pamela K Cassiday; Chuen-Sheue Chiang; Tine Dalby; Norman K Fry; María Emilia Gaillard; Marjolein van Gent; Nicole Guiso; Hans O Hallander; Eric T Harvill; Qiushui He; Han G J van der Heide; Kees Heuvelman; Daniela F Hozbor; Kazunari Kamachi; Gennady I Karataev; Ruiting Lan; Anna Lutyńska; Ram P Maharjan; Jussi Mertsola; Tatsuo Miyamura; Sophie Octavia; Andrew Preston; Michael A Quail; Vitali Sintchenko; Paola Stefanelli; M Lucia Tondella; Raymond S W Tsang; Yinghua Xu; Shu-Man Yao; Shumin Zhang; Julian Parkhill; Frits R Mooi
Journal:  mBio       Date:  2014-04-22       Impact factor: 7.867

View more
  1 in total

1.  Isolate-Based Surveillance of Bordetella pertussis, Austria, 2018-2020.

Authors:  Adriana Cabal; Daniela Schmid; Markus Hell; Ali Chakeri; Elisabeth Mustafa-Korninger; Alexandra Wojna; Anna Stöger; Johannes Möst; Eva Leitner; Patrick Hyden; Thomas Rattei; Adele Habington; Ursula Wiedermann; Franz Allerberger; Werner Ruppitsch
Journal:  Emerg Infect Dis       Date:  2021-03       Impact factor: 6.883

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.